Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Extracellular vesicles (EVs) are diverse nanoparticles with large heterogeneity in size and molecular composition. Although this heterogeneity provides high diagnostic value for liquid biopsy and confers many exploitable functions for therapeutic applications in cancer detection, wound healing and neurodegenerative and cardiovascular diseases, it has also impeded their clinical translation—hence heterogeneity acts as a double-edged sword. Here we review the impact of subpopulation heterogeneity on EV function and identify key cornerstones for addressing heterogeneity in the context of modern analytical platforms with single-particle resolution. We outline concrete steps towards the identification of key active biomolecules that determine EV mechanisms of action across different EV subtypes. We describe how such knowledge could accelerate EV-based therapies and engineering approaches for mimetic artificial nanovesicle formulations. This approach blunts one edge of the sword, leaving only a single razor-sharp edge on which EV heterogeneity can be exploited for therapeutic applications across many diseases. This Review presents a path to strategically overcoming extracellular vesicle heterogeneity and assay standardization, and offers solutions for realizing the clinical translation of extracellular vesicles for diagnostics and nanotherapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 5×
“Removing or blocking specific physiochemical components can be used to identify functional molecules 59,78,95,111 .”
InfluentialEngineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Tumour exosome integrins determine organotropic metastasis
Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. (2015) · Nature · doi:10.1038/nature15756 · Cited by 5,101 · cited 4×
“The efficiency of drug encapsulation across EVs, with respect to size or the density of a desired surface marker, are mostly unknown, despite the use of surface expression to dictate the EV fate 6 and function 52 .”
InfluentialWelsh, J. A., Goberdhan, D. C. I., O'Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., Cai, H., Di Vizio, D., Driedonks, T. A. P., Erdbrügger, U., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12404 · Cited by 4,663
Self-citationKowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426
Reassessment of exosome composition
Jeppesen, D. K., Fenix, A. M., Franklin, J. L., Higginbotham, J. N., Zhang, Q., Zimmerman, L. J., Liebler, D. C., Ping, J., Liu, Q., Evans, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.029 · Cited by 2,975 · cited 1×
“Whereas bulk analyses have uncovered thousands of EV-associated biomolecules, single-EV analysis reveals that each vesicle carries only a small subset 45 .”
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · cited 6×
“Multiple studies have examined the knockout, knock-in or mutation of molecules to identify functional differences in EV subpopulations 78,112,113 .”
InfluentialWiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730 · cited 1×
“Others appear to have organotropic character to target specific cells within distant tissues (although only a few precise mechanisms have been identified so far 6 ), impacting cell communication 6–8 , migration 9,10 , differentiation 11,12 and proliferation 13,14 .”
EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research
EV-TRACK Consortium, Van Deun, J., Mestdagh, P., Agostinis, P., Akay, Ö., Anand, S., Anckaert, J., Martinez, Z. A., Baetens, T., Beghein, E., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4185 · Cited by 1,284 · cited 1×
“In recent years, there have been substantial improvements 93 , in part associated with a field-wide movement towards reproducibility, which includes efforts such as the minimal information for studies of extracellular vesicles (MISEV) guidelines 94,95 and EV-TRACK 96 .”
Banks, W. A., Sharma, P., Bullock, K. M., Hansen, K. M., Ludwig, N., & Whiteside, T. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124407 · Cited by 561 · cited 2×
“…EV therapeutics are (1) high cellular uptake 78,79 , (2) cell/tissue tropism 6 , (3) immunomodulation 78,80 , (4) endothelial barrier crossing 21,81 , (5) protective effects (for example, neuroprotection) 82,83 , (6) regenerative properties (for example, angiogenesis) 84–87 and (7) cell…”
Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles
Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., & Karamanos, Y. (2020) · Cells · doi:10.3390/cells9040851 · Cited by 503
Cheng, K., Zhao, R., Li, Y., Qi, Y., Wang, Y., Zhang, Y., Qin, H., Qin, Y., Chen, L., Li, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22308-8 · Cited by 480 · cited 1×
“For example, the bacterial cytolytic toxin ClyA has been attached to bacteria-derived vesicles using a SpyCatcher/SpyTag pair and a SnoopCatcher/ SnoopTag pair 138 .”
Approaches to surface engineering of extracellular vesicles
Richter, M., Vader, P., & Fuhrmann, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.020 · Cited by 258
Lee, E. J., Choi, Y., Lee, H. J., Hwang, D. W., & Lee, D. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01356-2 · Cited by 89 · cited 1×
“Frequently, this is a top-down approach, first identifying the cells that produce EVs with a given function, and then comparing those EVs to identify similar physiochemical features 6,105 .”
A novel population of extracellular vesicles smaller than exosomes promotes cell proliferation
Lee, S.-S., Won, J.-H., Lim, G. J., Han, J., Lee, J. Y., Cho, K.-O., & Bae, Y.-K. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0401-z · Cited by 79
Cited by
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 269
Metadata
- Authors
- Carney, R. P., Mizenko, R. R., Bozkurt, B. T., Lowe, N., Henson, T., Arizzi, A., Wang, A., Tan, C., & George, S. C.
- Venue
- Nature Nanotechnology
- Published
- 2024-10-28
- Volume
- 20
- Issue
- 1
- Pages
- 14-25
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W4403839450
- Cited by
- 208
- References
- 16
- FWCI
- 24.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.